Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening (MEDLUNG)

NCT00899262 is registered in ClinicalTrials.gov with South West Wales Cancer Institute as lead sponsor.

NCT NCT00899262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00899262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening (MEDLUNG)
Lead sponsor
South West Wales Cancer Institute
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2008
Completion date
Not reported
Enrollment
300 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, tobacco use disorder